Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Drug Resistant Epilepsy × Sirolimus × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Tuberous Sclerosis 2 Myelodysplastic Syndromes 2 Lymphangioleiomyomatosis 2 Leukemia, Myeloid, Acute 2 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2 Hodgkin Disease 2 Graft vs Host Disease 2 Carcinoma, Hepatocellular 2 Waldenstrom Macroglobulinemia 1 Urinary Bladder Neoplasms 1 Skin Neoplasms 1 Rhabdomyosarcoma, Embryonal 1 Rhabdomyosarcoma, Alveolar 1 Rhabdomyosarcoma 1 PRETEXT I Hepatoblastoma 1 Myeloproliferative Disorders 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large B-Cell, Diffuse 1 Leukemia, Prolymphocytic, T-Cell 1 Leukemia, Prolymphocytic 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hematologic Neoplasms 1 Epilepsy 1 Drug Resistant Epilepsy 1 Breast Neoplasms 1 Birt-Hogg-Dube Syndrome 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05534672 2023-08-08

RaRE-TS

Children's Memorial Health Institute, Poland

Phase 3 Recruiting

Drug Resistant Epilepsy, Epilepsy, Tuberous Sclerosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡